Welcome. If you're a registered user, please log-in. If not, please sign-up.
Introducing our New BPI Europe App!
Industry Updates
FierceBiotech >profile  '@PatientsLikeMe opens up for patient-reported outcomes http://t.co/oiA3SGG3mE yesterday. · reply · retweet · favorite
FierceBiotech >profile  Pfizer denies knowledge of acquired companies' failures in East German drug trials http://t.co/0Q6AhEnzb0 yesterday. · reply · retweet · favorite
FierceBiotech >profile  The latest in the Elan saga, via @RyanMFierce: Amid deal frenzy, Elan rejects latest buyout bid from Royalty Pharma http://t.co/WQnM51vxcN yesterday. · reply · retweet · favorite
FierceBiotech >profile  RT @EmilyMFierce: Does the mistake in the OHSU embryonic stem cell study undermine all stem cell research? Interested in hearing your thoughts. yesterday. · reply · retweet · favorite
FierceBiotech >profile  RT @DamianFierce: Intuitive won its first da Vinci lawsuit, dodging $8.5M in damages. http://t.co/F77hTcvOO9 $ISRG yesterday. · reply · retweet · favorite
FierceBiotech >profile  Check out this week's roundup of job changes in #biopharma http://t.co/qDoYHdut5D via @MichaelGFierce and @EmilyMFierce yesterday. · reply · retweet · favorite
FierceBiotech >profile  Aveo shares shellacked after Astellas drops EU game plan on kidney cancer http://t.co/2jbJfM5S04 via @JohnCFierce yesterday. · reply · retweet · favorite
FierceBiotech >profile  Merck marks another failure in elusive hunt for Parkinson's disease drugs http://t.co/BgqB6cN38f via @RyanMFierce yesterday. · reply · retweet · favorite
FierceBiotech >profile  Studies dismiss cancer drug as powerful #Alzheimer's remedy http://t.co/pjSuW9aVVc 2 days ago. · reply · retweet · favorite
FierceBiotech >profile  Trending: Top 10 #Biotech CEO Pay Packages of 2012 http://t.co/fmQldheWKh 2 days ago. · reply · retweet · favorite
FierceBiotech >profile  Trending on @FierceMedDev: 2013's biggest job-cutters in medical devices and #diagnostics (so far) http://t.co/wjHOaDh57n via @DamianFierce 2 days ago. · reply · retweet · favorite
FierceBiotech >profile  Tantalizing data underscores #depression-fighting potential for party drug http://t.co/BHyDHz7IYR #biotech 2 days ago. · reply · retweet · favorite
FierceBiotech >profile  RT @DamianFierce: Here are the highlights of #EuroPCR's third day, starring $STJ, $BSX and CardioKinetix. http://t.co/Jsn60iqjZM 2 days ago. · reply · retweet · favorite
FierceBiotech >profile  RT @EmilyMFierce: Continuing the trend of #antibiotics news from yesterday: Cardeas banks $34M round for PhII antibiotic http://t.co/6R3BkYD9qf 2 days ago. · reply · retweet · favorite
FierceBiotech >profile  Cash-strapped #biotech fails PhIII test for pioneering Fragile X drug http://t.co/sieUh3yWL9 via @RyanMFierce #trials 2 days ago. · reply · retweet · favorite
..
100+ Speakers Including
100+ Speakers Including
Dr Morrey Atkinson, Vice President, Process Sciences, Bristol Myers Squibb, USA
Dr Stefanos Grammatikos, Head of Biological, Process Development UCB Pharma, Belgium
Professor Rolf G Werner, Industrial Biotechnology University of Tuebingen, Germany
Dr Christian Hicks, Professor of Operations Management Newcastle University Business School, UK
5 Co-Located Conferences
5 Co-Located Conferences
Jürgen Hubbuch, Professor Karlsruher Institut für Technologie (KIT), Germany
Dr Thomas Linden Executive Director, Protein Purification Development, Merck & Co, USA
Dr Hitto Kaufman VP, Process Development Boehringer Ingelheim, Germany
Dr Joanne Beck VP, Process Development, Shire, USA
11 hours of Unrivalled Networking

Online Partnering Tool

Pre-arrange meetings prior to the event

Speed Partnering

Meet more contacts in 30 minutes than you would in 2 days  

Networking Dinner - Sold out in 2012

Dance the night away at the BPI Networking Dinner

Present a Poster

Raise your profile by at the BPI Europe poster awards
..
Feeds
rss
Like
Share
twitterfacebooklinkedinemail
7 Seperately Bookable Workshops

QbD, Tech Transfer, Raw Materials, Biosimilars, ADCs, Reducing Costs

15+ Brand New Sessions

ADCs, Biosimilars, Raw Materials, Flexible Manufacturing, Host Cell Proteins, Innovations in DSP...

100+ Scientific Presentations

Reduce costs, improve quality and optimise bioprocessing

75+ Exhibitors and Growing

Evaluate New Processing Technologies and Services in One Venue

BPI Europe is THE meeting place for bringing together the latest processes, technologies and strategies driving every stage of biomanufacturing

Production of Biosimilars, ADCs and Antibodies

  1. Biosimilars and Antibody Drug Conjugates Production

  2. Cell Culture and Upstream Processing 

  3. Downstream Process Development

  4. Process, Product and Particle Characterisation

  5. Flexible Manufacturing and Tech Transfer

Events Updates and Interviews

Evolving strategies for successfully developing biosimilars and non-platformed therapeutics

Next-generation therapies such as bi-specifics, fusion proteins and fragments offer tremendous benefits on paper, but it’s the bioprocessing departments that have to develop the new production methods, switch to new platforms and investigate new capture steps. More

Reasons why your competitors are coming in April

  • Overcome the unique production challenges facing the manufacture of ADCs with unpublished case studies from Seattle Genetics, Immunogen, Ambrx, Agensys and ADC Therapeutics
  • Take advantage of the rapidly expanding biosimilar market by benchmarking your process development strategies against experienced developers Celltrion, Sandoz, Boehringer Ingelheim, Eden Biodesign, Intas, Synthon – how can you optimise biosimilar production whilst ensuring quality and similarity?
  • Find out how industry leaders GSK, Shire and Sartorius are capitalising on the benefits offlexible manufacturing to reduce facility footprints, minimise costs and prepare for the next wave of therapies such as orphan drugs
  • Reduce the cost of DSP by identifying cutting-edge enabling technologies and new strategies such as HTPD with case studies from Merck, KIT and Boehringer
  • Understand the immediate versus long term impact the CHO Genome Project will have on the Industry and commercial manufacturing with the latest research findings from University of Natural Resources and University of Lausanne
  • Design your process to ensure you get CQAs earlier on in the development process withcase studies from IBET, University of Birmingham and Sandoz Biopharmaceuticals

Special Rates for Pharma, SMEs and Academics

 

  • Academic Prices- Flat Rate £499.
  • SME/Industry Start Ups 50% Off Current Price Tier

Join our Social Networking sites...

 Follow us on Twitter @BPIEurope #BPI2013

   Join BioProcessing Professionals Europe and network with the most senior members of the industry

  Get the latest industry news on BioProcess International Blog

Follow BPI Europe on MyNewsDesk

Event Countdown

 
..

Corporate Sponsors

..
..
..
..

Associate Sponsors

..
..
..
..

Featured Exhibitors

..
..

Inventory Sponsor

..
..
..
..

In Association with

..
..
..
..

With thanks to our Media Partners

..